Latest Tax Incentives News

Actinogen Medical’s pivotal XanaMIA trial clears a key interim hurdle with the Data Monitoring Committee endorsing continuation, while a $16.8 million capital raise and non-dilutive funding bolster its balance sheet ahead of final results due November 2026.

Omega Oil and Gas has secured a commanding acreage position in Queensland’s Taroom Trough and fully funded an expanded drilling program to accelerate appraisal and early production.

Parkway Corporate Limited delivered a record $5.21 million quarterly revenue and $0.73 million EBITDA in Q3 FY26, driven by ramp-up of a major water infrastructure project. Meanwhile, its flagship Queensland Brine Management Complex progresses through key development application milestones with public notification underway.

Strategic Elements Ltd (ASX:SOR) advanced its Energy Ink™ technology and commenced a pilot deployment of its EdgeiQ system at a WA gold mine, while maintaining a solid cash position of A$2.87 million and no debt.

Janus Electric has begun generating export revenue in the US while expanding its electric truck fleet to 28 vehicles and significantly improving its cash position through a $1.4 million R&D tax refund and a $2.75 million finance facility.

Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.

CONNEQT Health’s Pulse device sales surged to a $7 million annualised run-rate despite a temporary supply hiccup, while the company manages a tight cash runway supported by new R&D loans and related-party funding.

OncoSil Medical reported a 60% year-on-year increase in dose sales in Q3 FY26, boosted by expanding treatment centres and advancing clinical trials, while cost-cutting and a new manufacturing facility aim to underpin growth.

Entropy Neurodynamics has reported encouraging early clinical outcomes from its pioneering intravenous psilocin therapy for Binge Eating Disorder, alongside a patent grant that strengthens its intellectual property moat.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

St George Mining has expanded its Araxá rare earths-niobium resource by 75% to 70.91Mt at 4.06% TREO, positioning the project among the world’s largest carbonatite deposits. The company also acquired land for processing facilities and forged new downstream partnerships, supported by Minas Gerais state tax incentives.

Metals Australia’s new PEA for its Quebec Battery Anode Material Refinery reveals robust economics with a $2.05 billion USD pre-tax NPV and a 25.6% IRR, underpinning plans for a final feasibility study.